Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Developments for Personalized Medicine of Lung Cancer Subtypes: Mass Spectrometry-Based Clinical Proteogenomic Analysis of Oncogenic Mutations.

Advances in experimental medicine and biology - 1 Jan 2016

Nishimura Toshihide, Nakamura Haruhiko

Abstract excerpt

Molecular therapies targeting lung cancers with mutated epidermal growth factor receptor (EGFR) by EGFR-tyrosin kinase inhibitors (EGFR-TKIs), gefitinib and erlotinib, changed the treatment system of lung cancer. It was revealed that drug efficacy differs by race (e.g., Caucasians vs. Asians) due to oncogenic driver mutations specific to each race, exemplified by gefitinib / erlotinib. The molecular target drugs...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma of Lung
Share to Erlotinib Hydrochloride

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Gefitinib

Share to Oncogene Proteins, Fusion

Share to Protein Interaction Mapping

Share to Proto-Oncogene Proteins c-ret

Share to Quinazolines

Share to Receptor, ErbB-2

Source

Identifiers

PMID: 27686809
DOI: 10.1007/978-3-319-42316-6_8

Genes

EGFR
ALK
EML4
RET
ROS1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Developments for Personalized Medicine of Lung Cancer Subtypes: Mass Spectrometry-Based Clinical Proteogenomic Analysis of Oncogenic Mutations.PMID 27686809Read ↗

Current status of clinical proteogenomics in lung cancerSemantic proximity Read ↗

Exploring AI tools and multi-omics for precision medicine in lung cancer therapy.Semantic proximity Read ↗

Proteogenomic characterization identifies clinical subgroups in EGFR and ALK wild-type never-smoker lung adenocarcinoma.Semantic proximity Read ↗

Recent Advances in Personalized Lung Cancer MedicineSemantic proximity Read ↗

The Role of Proteomics and Phosphoproteomics in the Discovery of Therapeutic Targets and Biomarkers in Acquired EGFR-TKI-Resistant Non-Small Cell Lung Cancer.Semantic proximity Read ↗

Personalized targeted therapy for lung cancer.Semantic proximity Read ↗

Unveiling the potential of proteomic and genetic signatures for precision therapeutics in lung cancer managementSemantic proximity Read ↗

Personalized Medicine and Proteomics: Lessons from Non-Small Cell Lung CancerSemantic proximity Read ↗

Personalized Cancer Medicine: Molecular Diagnostics, Predictive biomarkers, and Drug ResistanceSemantic proximity Read ↗

Integrated Multi-Omics and Transcriptomic Validation Analysis of TP53, ATM, BRCA1, EGFR, and KRAS Reveals Prognostic Significance in Lung CancerSemantic proximity Read ↗

Bioinformatics analysis of NSCLC multi-omics dataSemantic proximity Read ↗

Quantitative mass spectrometry to interrogate proteomic heterogeneity in metastatic lung adenocarcinoma and validate a novel somatic mutation CDK12-G879VSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.